Regeneron’s stock price movement
On October 15, Regeneron (REGN) closed at $377.55, which was 1.72% lower than its previous closing price on October 12. On October 15, the company had a market capitalization of $40.08 billion.
Regeneron and Sanofi (SNY) are awaiting the FDA’s decision regarding Dupixent in its asthma indication by the Prescription Drug User Fee Act (or PDUFA) date of October 20. A potential approval can support the company’s stock in October.
Regeneron (REGN) is currently trading 33.94% higher than its 52-week low price of $281.89 and 16.76% lower than its 52-week high price of $453.55. Based on its closing price on October 15, the company has returned -4.21%, -3.73%, and 3.32%, respectively, in the last week, the last month, and the last quarter. Regeneron has returned 17.02%, -14.77%, and 0.42%, respectively, in the last half year, the last year, and year-to-date.
Analysts’ recommendations and target price for Regeneron
The 12-month consensus analyst recommendation for Regeneron (REGN) on October 16 is a “hold.” The 12-month consensus target price for the company is $408.14, which is 8.1% higher than its last closing price on October 15. The highest target price estimate for the company is $512.00, and the lowest target price estimate is $305.00.
Of the 26 analysts covering Regeneron in the first half of October, eight analysts gave positive recommendations for the stock. Four analysts rated the company as a “strong buy,” and four analysts rated the company as a “buy.” Seventeen analysts rated the company as a “hold,” and one analyst rated the company as a “sell.”
At the end of the second quarter, Regeneron had $1.68 billion in cash on its balance sheet. The company also carries $705.9 million in debt on its balance sheet.
In the next article, we’ll discuss Regeneron’s NASH strategy and Alnylam Pharmaceuticals’ stock performance.